What Is CKM Syndrome? How Heart, Kidney, and Metabolic Health Are Connected

Cardiovascular-kidney-metabolic syndrome, usually shortened to CKM syndrome, is a framework for understanding how metabolic health, kidney health and cardiovascular health affect one another. Rather than treating obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease as completely separate problems, CKM recognizes that they often develop through overlapping biological pathways and can amplify one another over time.

The American Heart Association (AHA) formally introduced the CKM syndrome framework in 2023. In June 2026, the AHA, American College of Cardiology, American Diabetes Association and American Society of Nephrology published the first comprehensive clinical practice guideline for preventing, detecting, evaluating and managing CKM syndrome. The guideline reflects a shift toward looking at a person’s combined cardiovascular, kidney and metabolic risk rather than managing each condition in isolation.

CKM syndrome does not mean that everyone has heart disease, kidney disease and diabetes at the same time. The framework covers a spectrum ranging from early metabolic changes to established cardiovascular disease. Understanding those connections can help explain why detecting metabolic and kidney abnormalities earlier may be important for long-term cardiovascular health.

What does CKM syndrome mean?

CKM stands for cardiovascular-kidney-metabolic. Each part of the name represents a major component of the syndrome.

Cardiovascular refers to the heart and blood vessels. Cardiovascular disease can include conditions such as coronary heart disease, heart failure, stroke, atrial fibrillation and peripheral artery disease.

Kidney refers primarily to chronic kidney disease (CKD) and the ways changes in kidney function can interact with cardiovascular and metabolic health.

Metabolic refers to processes involved in how the body stores and uses energy. In the CKM framework, important metabolic factors include excess or dysfunctional adipose tissue, insulin resistance, prediabetes, type 2 diabetes, high blood pressure, abnormal blood lipids and related metabolic abnormalities.

The 2026 CKM guideline describes the syndrome as an interconnected condition involving metabolic risk factors—including obesity and type 2 diabetes—chronic kidney disease and cardiovascular disease.

This broader definition matters because a person does not need to wait until several advanced diseases appear simultaneously to fit into the CKM framework. Earlier metabolic abnormalities may signal the beginning of a process that can eventually affect the kidneys, blood vessels and heart.

Why are heart, kidney and metabolic health connected?

The organs and systems involved in CKM syndrome continuously influence one another. Blood vessels carry oxygen and nutrients to the kidneys and other tissues. The kidneys help regulate fluid balance, electrolytes and blood pressure. Hormonal and metabolic signals affect how the body handles glucose, fat and energy. When problems develop in one part of this network, the effects can spread.

The AHA’s scientific statement on CKM syndrome describes a multidirectional relationship among dysfunctional or excess adipose tissue, metabolic risk factors, kidney disease and cardiovascular disease. Important biological processes include insulin resistance, inflammation, oxidative stress and vascular dysfunction. These processes can contribute to metabolic abnormalities while also affecting kidney tissue, arteries and the heart.

The result is not necessarily a simple sequence in which one condition always causes the next. CKM can involve feedback loops in which several problems reinforce each other.

Metabolic dysfunction can affect the heart and kidneys

Adipose tissue does more than store energy. When adipose tissue becomes excessive or dysfunctional—particularly when fat accumulates around abdominal organs—it can produce metabolic and inflammatory changes.

These changes can contribute to insulin resistance, meaning the body’s cells respond less effectively to insulin. Over time, insulin resistance may contribute to prediabetes or type 2 diabetes. It is also commonly associated with abnormal blood pressure, triglycerides and other cardiovascular risk factors.

Persistent metabolic abnormalities can damage blood vessels throughout the body, including the small vessels that support kidney function. They can also increase the workload placed on the cardiovascular system.

This does not mean everyone with excess body weight will develop CKM complications. People with similar body weights can have very different metabolic profiles and cardiovascular risks. The CKM framework therefore looks beyond body weight alone.

Kidney disease can raise cardiovascular risk

The connection also works in the other direction. Chronic kidney disease is not solely a kidney problem.

As kidney function declines, disturbances involving blood pressure, fluid regulation, vascular health, inflammation and other physiological processes can contribute to cardiovascular risk. People with CKD have increased risks of cardiovascular complications, and CKD therefore plays a central role in CKM staging and risk assessment.

Kidney disease may also exist without obvious symptoms, particularly during earlier stages. That is one reason CKM assessment may include measures of kidney filtration and urine albumin rather than relying on how someone feels.

Heart and kidney problems can reinforce each other

The relationship between the heart and kidneys has long been recognized through the concept of cardiorenal syndrome. Reduced heart function can impair blood flow and contribute to kidney dysfunction, while kidney dysfunction can create physiological conditions that place additional stress on the cardiovascular system.

The CKM framework expands this concept by recognizing that metabolic factors can influence—and be influenced by—both systems. The 2023 AHA advisory specifically highlighted this multidirectional cardiovascular-kidney-metabolic interaction rather than treating cardiorenal and metabolic disorders as separate clinical silos.

Is CKM syndrome the same as metabolic syndrome?

No. The concepts overlap, but they are not interchangeable.

Metabolic syndrome refers to a cluster of metabolic risk factors such as abdominal obesity, elevated blood pressure, abnormal blood glucose and abnormal lipid levels. It is an important marker of cardiometabolic risk.

CKM syndrome takes a broader view. It incorporates metabolic dysfunction but also explicitly includes chronic kidney disease, subclinical cardiovascular disease, established cardiovascular disease and cardiovascular risk prediction.

Similarly, CKM is broader than cardiorenal syndrome because it incorporates metabolic health into the relationship between the cardiovascular and kidney systems.

One useful way to think about the distinction is that metabolic syndrome describes an important cluster of metabolic risk factors, while CKM syndrome provides a broader multiorgan framework for understanding how metabolic risk, kidney disease and cardiovascular disease can develop and interact across a person’s lifespan.

Who can have CKM syndrome?

CKM syndrome is not restricted to people who already have diabetes or diagnosed heart disease.

Depending on their health profile, people within the CKM spectrum may have excess or dysfunctional adiposity, prediabetes, hypertension, high triglycerides, metabolic syndrome, type 2 diabetes, chronic kidney disease, evidence of cardiovascular changes that have not yet produced symptoms, or established cardiovascular disease.

Someone can therefore enter the CKM framework well before a heart attack, stroke or other major cardiovascular event occurs.

It is also possible to have important CKM risk without obesity. For example, prediabetes or kidney disease can contribute to CKM classification depending on the person’s overall health profile. Conversely, body weight by itself does not reveal someone’s complete metabolic, kidney or cardiovascular risk.

Age, genetics, health behaviors, access to health care and social determinants of health can also influence CKM risk and progression. The AHA advisory emphasizes that social and structural factors—including access to nutritious food, opportunities for physical activity and health care resources—can affect CKM prevention and treatment.

How CKM syndrome is staged

One of the defining features of the CKM framework is its staging system.

Although people often refer casually to “Stages 0 through 4,” the updated framework makes an important distinction: Stage 0 represents ideal CKM health and people who do not have CKM syndrome, while Stages 1 through 4 describe progressively more significant CKM abnormalities.

At a high level:

CKM stage	General meaning
Stage 0	No identified CKM risk factors; represents ideal CKM health rather than CKM syndrome
Stage 1	Early metabolic changes, such as excess weight or dysfunctional adiposity and/or prediabetes
Stage 2	Metabolic risk factors and/or chronic kidney disease
Stage 3	Subclinical cardiovascular disease, very high cardiovascular risk or very high-risk kidney disease
Stage 4	Established clinical cardiovascular disease in the setting of CKM risk

The stages are intended to help clinicians recognize risk earlier and match prevention or treatment intensity to a person’s overall health profile. They are not simply a prediction that everyone will inevitably move from one stage to the next.

For a more detailed explanation of the criteria and what changes from one stage to another, see our guide to how the CKM stages differ.

CKM syndrome does not always cause symptoms

A major reason the CKM framework emphasizes early detection is that risk can develop before a person feels unwell.

High blood pressure, prediabetes, early type 2 diabetes and chronic kidney disease can all be present with few or no obvious symptoms. Stage 3 CKM can include subclinical cardiovascular disease, meaning changes are detectable through clinical assessment or testing even though the person may not have recognizable cardiovascular symptoms.

This means symptoms alone cannot determine whether someone has CKM syndrome or what stage they may be in.

Later CKM stages may involve symptoms associated with established cardiovascular or advanced kidney disease, but those symptoms depend on the specific condition involved. Chest discomfort, shortness of breath, swelling, weakness or exercise intolerance, for example, can have many possible causes and should not be used to self-diagnose CKM syndrome.

A separate article in this series examines CKM symptoms and warning signs in detail.

How common is CKM syndrome?

CKM syndrome is a relatively new clinical framework, so prevalence estimates depend on how researchers translate the staging criteria into available population datasets.

One influential 2024 analysis used National Health and Nutrition Examination Survey data collected from U.S. adults between 2011 and March 2020. Researchers estimated that 10.6% met Stage 0 criteria, 25.9% Stage 1, 49.0% Stage 2, 5.4% Stage 3 and 9.2% Stage 4 criteria. Together, 14.6% were classified in advanced Stages 3 or 4.

Those figures require context. They are estimates based on historical survey data and researchers’ application of CKM definitions; they should not be interpreted as a direct measurement of CKM prevalence in the U.S. population in 2026. The authors also had to adapt some staging criteria to the information available in NHANES.

Even with those limitations, the study illustrates why CKM has become an important public-health concept: metabolic, kidney and cardiovascular abnormalities overlap in a substantial portion of adults.

Why the CKM framework matters

Before CKM syndrome was formally defined, clinicians already understood that obesity, diabetes, kidney disease and cardiovascular disease were connected. What CKM provides is a more unified framework for identifying and managing those connections.

That matters in several ways.

It encourages earlier prevention

CKM staging begins before clinical cardiovascular disease develops. Instead of waiting until someone experiences a heart attack, stroke or heart failure, the framework encourages recognition of metabolic and kidney abnormalities that can contribute to later cardiovascular risk.

The 2026 guideline recommends CKM staging to help prevent progression, tailor treatment to risk and, when possible, promote movement toward healthier stages.

It broadens cardiovascular risk assessment

Traditional cardiovascular prevention has often centered heavily on cholesterol, blood pressure, smoking and diabetes. Those remain important, but CKM adds greater emphasis to factors such as kidney function, albumin in the urine, adiposity and heart-failure risk.

The guideline also incorporates the AHA’s PREVENT equations, which estimate risks of atherosclerotic cardiovascular disease, heart failure and total cardiovascular disease using cardiovascular, kidney and metabolic information. Detailed testing and risk assessment will be covered separately in the CKM screening article.

It supports coordinated care

A person with diabetes, kidney disease and cardiovascular risk might otherwise receive care from several clinicians who focus on individual conditions. CKM encourages a more integrated approach.

That can involve primary care clinicians, cardiologists, nephrologists, endocrinologists, pharmacists, dietitians and other professionals depending on a person’s needs. The goal is not simply to add more specialists, but to reduce fragmented decision-making when treatments or risk factors affect several organ systems simultaneously.

Does having CKM syndrome mean cardiovascular disease is inevitable?

No.

CKM staging describes a person’s current health and risk profile; it does not guarantee a particular outcome. People do not necessarily progress through the stages in a fixed, irreversible sequence.

The AHA’s current patient guidance notes that people can move between stages as health conditions improve or worsen. The 2026 guideline also places substantial emphasis on preventing stage progression and promoting stage regression through appropriate lifestyle changes, weight management and medical care when indicated.

The possibilities for improvement vary depending on the conditions present and whether organ damage has already occurred. Established cardiovascular or kidney disease cannot simply be assumed to reverse. However, controlling modifiable risk factors and treating existing conditions can still play an important role in reducing future complications.

What should someone do if they are concerned about CKM risk?

CKM syndrome cannot be determined from one symptom, one blood test or body weight alone.

A clinical assessment may consider factors such as blood pressure, waist circumference or BMI, glucose regulation, blood lipids, kidney function, urine albumin, medical history and cardiovascular risk. More specialized testing may be appropriate for some people based on their stage, symptoms and risk profile.

People who already have conditions such as hypertension, prediabetes, type 2 diabetes, obesity, chronic kidney disease or cardiovascular disease can ask a health care professional how those conditions affect their overall cardiovascular-kidney-metabolic risk.

The value of the CKM concept is not that everyone needs every available test. It is that relevant metabolic, kidney and cardiovascular information should be considered together rather than in isolation.

The bigger picture: CKM health is connected health

CKM syndrome provides a practical way to describe something medicine has increasingly recognized: metabolic health, kidney health and cardiovascular health are deeply interconnected.

Excess or dysfunctional adipose tissue and metabolic abnormalities can influence blood vessels and kidney function. Kidney disease can increase cardiovascular risk. Cardiovascular and kidney dysfunction can reinforce each other. These relationships can begin well before obvious symptoms or major cardiovascular events occur.

The CKM framework therefore shifts attention toward earlier identification, coordinated risk assessment and integrated prevention and treatment. It also gives clinicians and patients a common language for discussing health across systems that historically have often been managed separately.

For an individual reader, the most useful takeaway is not to try to assign yourself a CKM stage. Instead, CKM offers a framework for understanding why factors such as blood pressure, glucose, body composition, kidney function and cardiovascular risk deserve to be considered together.

This article provides general educational information and is not a substitute for individualized medical evaluation. CKM staging and treatment decisions should be based on a person’s complete clinical profile.

References

1. Ndumele CE, Rodriguez F, Dixon DL, et al. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome.” Circulation, 2026.
2. Ndumele CE, Rangaswami J, Chow SL, et al. “Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association.” Circulation, 2023;148:1606–1635.
3. Ndumele CE, Neeland IJ, Tuttle KR, et al. “A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association.” Circulation, 2023;148:1636–1664.
4. Aggarwal R, Ostrominski JW, Vaduganathan M. “Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011–2020.” JAMA, 2024;331(21):1858–1860.